Sandoz launches Zarxio (TM) (filgrastim-sndz), the first biosimilar in the United States

Launch follows March 6, 2015 FDA approval. Sandoz One SourceTM offers patient support services

Source: Pharmacy Europe - September 3, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Biosimilars Clinical trials Practical therapeutics Oncology fda approval filgrastim-sndz Latest News zarxio Source Type: news